As of 1 April 2026, the PSJD database will become an archive and will no longer accept new data. Current publications from Polish scientific journals are available through the Library of Science: https://bibliotekanauki.pl
A case of 73-year-old patient with metastatic colorectal cancer who underwent trifluridine/tipiracil therapy within the VI line was presented. Treatment with trifluridine/tipiracil allowed to achieve stabilization of the existing cancer for nearly 7 months.
1. Department of Oncology, Medical University of Bialystok, Poland. 2. Department of Oncology with Daytime Chemotherapy Unit, Bialystok Oncology Centre, Poland
1. Department of Oncology, Medical University of Bialystok, Poland. 2. Department of Oncology with Daytime Chemotherapy Unit, Bialystok Oncology Centre, Poland
1. Department of Oncology, Medical University of Bialystok, Poland. 2. Department of Oncology with Daytime Chemotherapy Unit, Bialystok Oncology Centre, Poland
References
1. Mayer RJ, Van Cutsem E, Falcone A et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015; 372(20): 1909-19.
2. Xu J, Kim TW, Shen L et al. Results of a randomized, double-blind, placebo-controlled, Phase III trial of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients With previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncol. 2018; 36(4): 350-8.
3. Kwakman JJM, Vink G, Vestjens JH et al. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. Int J Clin Oncol. 2018; 23: 482-9.
4. Cremolini C, Rossini D, Martinelli E et al. Trifluridine/tipiracil (TAS-102) in refractory metastatic colorectal cancer: a multicenter register in the frame of the Italian compassionate use program. Oncologist. 2018; 23: 1178-87.